A
Albiruni Ryan Abdul Razak
Researcher at Princess Margaret Cancer Centre
Publications - 253
Citations - 7154
Albiruni Ryan Abdul Razak is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 39, co-authored 195 publications receiving 5045 citations. Previous affiliations of Albiruni Ryan Abdul Razak include Harvard University & University Health Network.
Papers
More filters
Journal ArticleDOI
Deciphering primary and acquired immunotherapy resistance with whole genome and transcriptome analysis (WGTA).
Sofia Genta,Jeff Bruce,Xuan Li,Sam Felicen,Albiruni Ryan Abdul Razak,Samuel D. Saibil,Mark S. Butler,Philippe L. Bedard,Bernard C.-H. Lam,Ming-Sound Tsao,Wey L. Leong,Alexandra M. Easson,Ben X. Wang,Ilinca Lungu,David Goldstein,Aaron R. Hansen,Lawson Eng,Trevor J. Pugh,Lillian L. Siu,Anna Spreafico +19 more
TL;DR: Pérez-Guijarro et al. as mentioned in this paper found that the MPS signature was significantly associated with Pr vs Ar resistance in multivariable analysis ( p = 0.048).
Journal ArticleDOI
Abstract CT116: First-in-human study of AZD8853, an anti-growth and differentiation factor 15 (GDF15) antibody, in patients (pts) with advanced/metastatic solid tumors
Benedito A. Carneiro,Maria Diab,Brian A. Van Tine,Anthony F. Shields,Albiruni Ryan Abdul Razak,Joan F. Hilton,Rafael Santana-Davila,E. Sanaĭ,Jorge Zeron-Medina,Veronique Bragulat,Arthur W. Lambert,John Hood,Rajesh Kumar,Duncan I. Jodrell,Patricia LoRusso +14 more
TL;DR: CARNEIRO et al. as mentioned in this paper presented a Phase I/IIa, first-in-human, open-label study (NCT05397171) assessing the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD8853 in pts with histologically or cytologically confirmed locally advanced, unresectable or metastatic mismatch repair-proficient colorectal cancer (pMMR-CRC), non-small-cell lung cancer (NSCLC) and urothelial carcinoma (UC).
Journal ArticleDOI
Phase 1b study of weekly split-dose selinexor in soft tissue sarcoma (STS).
Abdulazeez Salawu,Abha A. Gupta,Esmail Mutahar Al-Ezzi,Sofia Genta,Eoghan Ruadh Malone,Tushar Vora,Geoffrey Alan Watson,Olga Vornicova,Lisa Wang,Limore Arones,Madeline Phillips,Jasmine Lee,Albiruni Ryan Abdul Razak +12 more
TL;DR: Split-dose selinexor was well tolerated in this heterogeneous group of pts with advanced STS and warrants further interrogation, and Updated toxicity, safety, efficacy and QoL data will be presented at the meeting.
Journal ArticleDOI
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors
Anthony B. El-Khoueiry,James Clarke,Tobias Neff,Nirav Ratia,Chetan Rathi,P. Noto,Aarti Tarkar,Ignacio Garrido-Laguna,Emiliano Calvo,Jordi Rodon,Ben Tran,Peter J. O'Dwyer,Adam Cuker,Albiruni Ryan Abdul Razak +13 more
TL;DR: GSK3368715, a first-in-class reversible inhibitor of type I protein methyltransferases (PRMTs), demonstrated anticancer activity in preclinical studies as mentioned in this paper .
Journal ArticleDOI
Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.
Robin L. Jones,Jean-Yves Blay,Suzanne George,Hans Gelderblom,Patrick Schöffski,Margaret von Mehren,John Zalcberg,Yoon-Koo Kang,Albiruni Ryan Abdul Razak,Jonathan C. Trent,Steven Attia,Axel Le Cesne,William M. Reichmann,Haroun Achour,Matthew L. Sherman,Rodrigo Ruiz-Soto,Sebastian Bauer,Michael Heinrich +17 more
TL;DR: The second interim analysis (IA) for overall survival (OS) in the INTRIGUE trial, data were immature (OS event rate, 22.3%), and median OS was not reached in either arm for the KIT exon 11 intent-to-treat (ITT) and all-patient (AP) ITT populations as mentioned in this paper .